June 18, 2019 08:49 AM EDTUpdated 11:09 AM
Bioregnum
Opinion

Af­ter watch­ing its share price soar on a Bloomberg re­port and heat­ed ru­mors, Bio­haven stock takes a bil­lion-dol­lar bath

Back in April, Bio­haven Phar­ma­ceu­ti­cal be­came one hot biotech stock $BHVN based on a re­port in Bloomberg that some “po­ten­tial bid­ders” had been kick­ing the tires at the biotech, which has a lead drug for mi­graines. Then the ru­mor mill re­al­ly start­ed to smoke when ex­ecs can­celed a pre­sen­ta­tion at an in­vestor con­fer­ence a lit­tle more than a week ago.

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times